Trial Profile
Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2014
Price :
$35
*
At a glance
- Drugs Alfuzosin (Primary)
- Indications Bladder dysfunction
- Focus Pharmacokinetics
- Acronyms ALFACHIP
- Sponsors Sanofi
- 26 Apr 2014 New trial record